Gilead Sciences (NQ:GILD)

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q3 2026 results exceeding the market’s revenue expectations, with sales up 6.8% year on year...

GILD Q3 deep dive: HIV franchise drives growth as policy headwinds loom

October 30, 2026

Base business sales surged 16%, marking strongest growth in over a decade.

S&P 500 Gap Movers for October 30, 2026 ↗

October 30, 2026

Via Chartmill

Topics Stocks

Gilead (GILD) Q3 2026 Earnings Call Transcript ↗

October 30, 2026

Gilead Sciences (NASDAQ:GILD) Posts Q3 Beat but Shares Stay Flat as Raised Guidance Is Roughly In Line ↗

Topics Earnings

October 29, 2026

Via Chartmill

S&P 500 Premarket Gainers and Losers on Oct. 30, 2026 ↗

October 30, 2026

Via Chartmill

Topics Stocks

What Gilead Sciences (GILD) Said on Its Q3 Earnings Call ↗

October 29, 2026

Gilead Sciences (NASDAQ:GILD) reported third-quarter 2026 base business sales growth of 16% year over year, its strongest growth rate in more than a decade, as HIV products, TRODELVY and Livdelzi drove...

Via MarketBeat

Topics Earnings

After-Hours S&P 500 Movers: Mondelez and FedEx Freight Gain, Intel and Reddit Fall ↗

October 29, 2026

Via Chartmill

Topics Stocks

Gilead Sciences (NASDAQ:GILD) surprises with Q3 2026 sales, full-year outlook slightly exceeds expectations

October 29, 2026

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) beat Wall Street’s revenue expectations in Q3 2026, with revenue up 6.8% year on year to $8.3 billion...

Gilead Sciences crushed Wall Street's sales expectations on the back of its HIV treatments and cancer drug Trodelvy.

How Gilead, Which Just Hit A Record, Notched Its Best Sales Growth In A Decade ↗

October 29, 2026

Via Investor's Business Daily

Gilead Sciences Announces Third Quarter 2026 Financial Results

October 29, 2026

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting results this Thursday after the bell. Here’s what you need to know. Gilead Sciences...

Gilead Sciences earnings: what to look for from GILD

October 27, 2026

Which Biotech ETF Is the Better Buy: VanEck’s BBH or Invesco’s Factor-Driven PBE? ↗

October 27, 2026

BBH offers lower costs and concentrated large-cap exposure, while PBE delivers higher dividend income and slightly better five-year returns through a multifactor strategy.

VanEck Biotech vs. Invesco Healthcare: Which ETF Offers More Potential for Long-Term Growth? ↗

Topics ETFs

October 25, 2026

These two healthcare ETFs offer investors exposure to some of medicine's biggest names, but their different approaches to investing could lead to very different results.

Both of these biotech stocks could be appealing to income investors.

Topics ETFs

Amgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy? ↗

October 25, 2026

Here's how pharmaceutical stocks compare to biotech in terms of risk, rewards, and costs.

Invesco Pharmaceuticals ETF vs. iShares Biotechnology ETF: Which Is the Better Buy? ↗

October 23, 2026

Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001, Strengthening Its Inflammation Pipeline in IBD

Topics ETFs

October 22, 2026

Gilead to Present New Data on Treatment Response and Long-Term Management of Rare Liver Diseases at The Liver Meeting® 2026

October 22, 2026

Both of these ETFs look the part, but only one is truly the better buy for investors.

Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy? ↗

October 22, 2026

Arcus Biosciences (NYSE:RCUS) presented updated clinical and translational data for casdatifan, its investigational HIF-2 alpha inhibitor, outlining development plans across first-line, second-line and...

Topics ETFs

Arcus Biosciences Sees $5B-$10B RCC Opportunity for Casdatifan at Investor Day ↗

October 21, 2026

Via MarketBeat

Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026

October 19, 2026

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to conv...

1 Unprofitable Stock with Exciting Potential and 2 We Find Risky

October 19, 2026

Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow? ↗

October 18, 2026

The company's recent momentum continues unabated.

Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements...

3 Inflated Stocks Walking a Fine Line

October 16, 2026

Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026

October 15, 2026

Better Invesco Healthcare ETF: PJP Targeting Pharmaceuticals vs. RSPH's Broader Sector Lens ↗

Top S&P500 movers in Wednesday's session ↗

October 14, 2026

Via Chartmill

Exploring the top movers within the S&P500 index during today's session. ↗

October 14, 2026

Via Chartmill

October 11, 2026

PJP's one-year return beats RSPH's, but RSPH offers broader diversification across 61 healthcare holdings at a lower expense ratio.

VanEck's lower 0.35% expense ratio appeals to cost-conscious investors, while First Trust's $2.9 billion in assets and equal-weighted approach offer broader diversification across 30 biotech holdings.

Topics ETFs

Better Biotechnology ETF: First Trust FBT vs. VanEck BBH ↗

October 10, 2026